Our Firm is actively filing Risperdal gynecomastia cases in this litigation, and we continue to hear from individuals who allegedly developed this painful and embarrassing condition due to the medication.
New York, New York (PRWEB) October 18, 2014
Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, 888 product liability claims have been filed in the proceeding on behalf of Risperdal patients who allegedly developed serious side effects, including gynecomastia (male breast growth), due to their use of the atypical antipsychotic medication. (In Re: Risperdal Litigation, Case Number 100300296).
“Our Firm is actively filing Risperdal gynecomastia cases in this litigation, and we continue to hear from individuals who allegedly developed this painful and embarrassing condition due to the medication. We are not surprised that that the number of claims pending in the proceeding is approaching 900,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
According to court documents, all of the Risperdal lawsuits pending in Pennsylvania accuse Johnson & Johnson and Janssen Pharmaceuticals of concealing drug’s serious side effects and of failing to warn doctors and patients of these risks, including its association with male breast growth. Plaintiffs also allege that the companies improperly marketed Risperdal for unapproved uses, including certain pediatric indications prior to their regulatory approval. The litigation’s first trial of a Risperdal case involving gynecomastia is scheduled to begin on November 3, 2014.
In November 2013, Johnson & Johnson and Janssen Pharmaceuticals agreed to pay $2.2 million to settle charges brought by the U.S. Department of Justice involving the marketing of Risperdal and other medications. While the companies did not admit any wrongdoing in resolving civil charges regarding the promotion of Risperdal for off-label use in children, they did plead guilty to a criminal misdemeanor and acknowledged that they had improperly marketed the drug for use in elderly dementia patients. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who allegedly developed gynecomastia due to Risperdal may be entitled to take legal action against the manufacturers of the medication. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com